Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Neu Isenburg, Germany Clinical Trials

A listing of Neu Isenburg, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (285) clinical trials

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

The purpose of the trial is to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 g and QVM149 150/50/160 g via Concept1) over two respective QMF149 doses (QMF149 150/160 g and QMF149 150/320 g via Concept1 in poorly controlled asthmatics as determined by pulmonary function ...

Phase

0.0 miles

Learn More »

A Multicenter Randomized 52 Week Treatment Double-blind Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma

The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 g and QMF149 150/320 g via Concept1) over two respective MF doses (MF 400 g and MF 800 g via Twisthaler (total daily dose)) in poorly controlled asthmatic patients as ...

Phase

0.0 miles

Learn More »

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to receive benefit. Subjects who participated in the open-label studies MEA115666 or 201312 with at least 6 ...

Phase

0.0 miles

Learn More »

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

This study will have a main 24-week treatment period and a 28-week extension period of treatment.

Phase

0.0 miles

Learn More »

Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis

The aim of this present study is to investigate the use of benralizumab as treatment for severe nasal polyposis. The effect of benralizumab on nasal polyps will be assessed over a 56 weeks of treatment period in patients with severe bilateral nasal polyposis who are still symptomatic despite standard of ...

Phase

1.57 miles

Learn More »

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country study in subjects with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 is designed to compare the achievement of minimal disease activity (MDA) between subjects randomized to either adalimumab in combination with methotrexate (MTX) or MTX alone escalated to the ...

Phase

3.0 miles

Learn More »

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee Hip or Shoulder Replacement

A4091064 is a long-term observational follow up study of subjects from tanezumab interventional studies A4091056, A4091057 or A4091058.

Phase

3.0 miles

Learn More »

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ) Compared to Placebo and Adalimumab in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

The goal of this Phase III study is to assess the safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who have responded inadequately to MTX. The primary endpoint of the trial is at Week 12. Olokizumab is expected to reduce the disease activity and ...

Phase

3.0 miles

Learn More »

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ) Compared to Placebo in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Disease

The goal of this Phase III study is to assess the safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who have responded inadequately to TNFi therapy. The primary endpoint of the trial is at Week 12. Olokizumab is expected to reduce the disease activity ...

Phase

3.0 miles

Learn More »

Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia

This is a randomised double-blinded placebo-controlled multi centre study in 98 patients with ACPA positive arthralgia. The study is composed of 2 arms with a 1:1 randomisation at baseline: Treatment phase will be 6 months. Group 1: Abatacept s.c. 125 mg weekly for 6 months vs. Group 2: Placebo s.c. ...

Phase

3.0 miles

Learn More »